phrykt

Lisata Therapeutics, Inc. (LSTA): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of LSTA were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No LSTA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LSTA short interest

Low short interest. 0.4% of LSTA shares are sold short: about 1 share in 264. Over the last 12 reports the number of shares short went down 63%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 34,163 LSTA shares were sold short, 0.4% of the shares outstanding, up 18.6% from the report before. At the average daily volume of 58,762 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.38%May 15Oct 302.06%

Days to cover

1.0May 15Oct 305.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202634,1630.38%+19%58,7621.0
Oct 15, 202628,7970.32%-27%151,1891.0
Sep 30, 202639,4070.44%-76%362,2561.0
Sep 15, 2026164,9531.83%+16%189,4661.0
Aug 31, 2026141,7981.57%+58%844,2231.0
Aug 14, 202689,8671.00%+60%78,7421.1
Jul 31, 202656,3410.62%-57%155,4281.0
Jul 15, 2026129,9201.44%+24%46,1672.8
Jun 30, 2026104,8131.16%+17%20,0265.2
Jun 15, 202689,5890.99%-28%201,1551.0
May 29, 2026124,1631.37%+33%220,5921.0
May 15, 202693,4931.04%+33%31,2493.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lisata Therapeutics company events

Lisata Therapeutics filed 16 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026LeadershipLisata Therapeutics, Inc. held its 2026 annual meeting of stockholders. Filing
  2. Oct 14, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee, the Board of Directors of Lisata Therapeutics, Inc. approved an increase in the size of the Board from seven to eight members and appointed Jeffrey Farrow as a Class III member of the Board to fill the newly created seat… Filing
  3. Sep 17, 2026LeadershipAppointment of Director In accordance with the Merger Agreement, on September 17, 2026, effective immediately after the First Effective Time, Ted W. Love, M.D. was appointed to the Board as a director. Filing
  4. Aug 4, 2026LeadershipIn connection with the reduction in workforce approved by the Board on August 3, 2026, effective as of August 3, 2026, the employment of Dr. Kristen K. Buck, M.D., the Company’s Executive Vice President of R&D and Chief Medical Officer was terminated. Filing
  5. Jul 24, 2026AnnouncementThe Company’s Board of Directors plans to conduct an assessment of strategic options to enhance stockholder value, which will include, but are not limited to, a reverse merger, other business combination, sales of assets, dissolution or other strategic transactions. Filing
  6. Jul 17, 2026AgreementLisata Therapeutics, Inc. and Kuva Labs Inc., a Delaware corporation, together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent, entered into an amendment to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among… Filing
  7. Jun 9, 2026AgreementLisata Therapeutics, Inc. and Kuva Labs Inc., a Delaware corporation, together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent, entered into an amendment and waiver to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by… Filing
  8. Jun 1, 2026AnnouncementAs previously announced, on May 29, 2026, Lisata Therapeutics, Inc. and Kuva Labs Inc., a Delaware corporation, together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent, entered into an amendment to the previously announced Agreement and Plan of Merger… Filing
  9. May 29, 2026AgreementLisata Therapeutics, Inc. and Kuva Labs Inc., a Delaware corporation, together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent, entered into an amendment to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among… Filing
  10. May 4, 2026AgreementLisata Therapeutics, Inc. and Kuva Labs Inc., a Delaware corporation, together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent, entered into an amendment and waiver to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by… Filing
  11. Apr 15, 2026AnnouncementAs previously disclosed, on April 2, 2026, Lisata Therapeutics, Inc. and Kuva Labs Inc., a Delaware corporation, together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent, agreed to extend the date by which Purchaser is obligated to commence the tender… Filing
  12. Apr 3, 2026AnnouncementLisata Therapeutics, Inc. and Kuva Labs Inc., a Delaware corporation, together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent, agreed to extend the date by which Purchaser is obligated to commence the tender offer for all of the outstanding shares of… Filing
  13. Mar 9, 2026AgreementLisata Therapeutics, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Kuva Labs Inc., a Delaware corporation, and Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent. Filing
  14. Feb 27, 2026AgreementReference is made to the binding term sheet, dated as of January 20, 2026, by and between Lisata Therapeutics, Inc. and Kuva Labs Inc., pursuant to which Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata… Filing
  15. Jan 27, 2026AnnouncementLisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. entered into a Mutual Termination Agreement relating to the Exclusive License and Collaboration Agreement between the Company (formerly Cend Therapeutics, Inc.) and Qilu, relating to the research, development and commercialization of… Filing
  16. Jan 21, 2026AgreementLisata Therapeutics, Inc., a Delaware corporation, entered into a binding term sheet with Kuva Labs Inc., a Delaware corporation, pursuant to which Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata by… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lisata Therapeutics financials

Famous investors that hold LSTA

1 of the 50 well-known investors we track reported holding LSTA in their latest 13F filing. The largest position is Ken Griffin's, worth $110K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202676,275$110K0.0%+391%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Lisata Therapeutics, Inc. (LSTA) stock

Are LSTA insiders buying or selling?

No LSTA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in LSTA?

As of Oct 30, 2026, 34,163 LSTA shares were sold short, 0.4% of the shares outstanding, up 18.6% from the report before. At the average daily volume of 58,762 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold LSTA?

1 of the 50 well-known investors we track reported LSTA in their latest 13F filing, including Ken Griffin. The largest position is worth $110K. See all holders.

Executive pay

Lisata Therapeutics's chief executive was paid a total of $1.1M for the year ended Dec 31, 2025, down 32% from $1.7M the year before. In the last 12 months, Lisata Therapeutics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$938KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$585KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.